Literature DB >> 31810853

Do Toxoplasma gondii apicoplast proteins have antigenic potential? An in silico study.

Hüseyin Can1, Sedef Erkunt Alak2, Ahmet Efe Köseoğlu2, Mert Döşkaya3, Cemal Ün2.   

Abstract

Toxoplasma gondii, one of the extensively studied Apicomplexan parasites, is prevalent worldwide in animals and humans. Apart from its nuclear genome, T. gondii contains an apicoplast genome in 35 kb length which is originated from a secondary endosymbiotic event. In this study, we aimed to investigate the antigenic potential of apicoplast genome encoded proteins (n:28) of T. gondii using in silico analysis. For this purpose, proteins were primarily predicted to reveal antigenic probability and then, several bioinformatics analyses were applied for all predicted antigenic apicoplast proteins to analyze physico-chemical parameters, subcellular localization and transmembrane domain. Also, further prediction analyses including structural, B cell and MHC-I/II epitope sites as well as post-translational modifications were performed for antigenic proteins that have a signal peptide or a high antigenicity value. Of the 28 apicoplast proteins, 19 were predicted as probable antigen. Among antigenic proteins, ribosomal protein S5, L11 and S2 were predicted to have signal peptide whereas ribosomal protein L36 and S17 were predicted to have a significantly high antigenicity value (P < 0.05). In addition, ribosomal protein S5, L11, S2, L36 and S17 were predicted to have a lot of epitopes which have low IC50 and percentile rank value indicating a strong binding among epitopes and MHC-I/II alleles, and post-translational modifications such as N-linked glycosylation, acetylation and phosphorylation. To the best of authors' knowledge this is the first study to show the antigenic potential and other properties of apicoplast-derived proteins of T. gondii.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antigen; Apicoplast; Epitope; Ribosomal protein; T. gondii; Vaccine

Mesh:

Substances:

Year:  2019        PMID: 31810853     DOI: 10.1016/j.compbiolchem.2019.107158

Source DB:  PubMed          Journal:  Comput Biol Chem        ISSN: 1476-9271            Impact factor:   2.877


  6 in total

1.  A negative covariation between toxoplasmosis and CoVID-19 with alternative interpretations.

Authors:  Łukasz Jankowiak; Lajos Rozsa; Piotr Tryjanowski; Anders Pape Møller
Journal:  Sci Rep       Date:  2020-07-27       Impact factor: 4.379

2.  In silico discovery of antigenic proteins and epitopes of SARS-CoV-2 for the development of a vaccine or a diagnostic approach for COVID-19.

Authors:  Hüseyin Can; Ahmet Efe Köseoğlu; Sedef Erkunt Alak; Mervenur Güvendi; Mert Döşkaya; Muhammet Karakavuk; Adnan Yüksel Gürüz; Cemal Ün
Journal:  Sci Rep       Date:  2020-12-28       Impact factor: 4.379

3.  Role of interferon gamma in SARS-CoV-2-positive patients with parasitic infections.

Authors:  Enas Fakhry Abdel-Hamed; Mohamed N Ibrahim; Nahed E Mostafa; Howayda S F Moawad; Nahla E Elgammal; Ehab M Darwiesh; Dina S El-Rafey; Nissreen E ElBadawy; Emad Ali Al-Khoufi; Salwa I Hindawi
Journal:  Gut Pathog       Date:  2021-05-04       Impact factor: 4.181

4.  Immunoinformatic Analysis of Calcium-Dependent Protein Kinase 7 (CDPK7) Showed Potential Targets for Toxoplasma gondii Vaccine.

Authors:  Ali Taghipour; Sanaz Tavakoli; Mohamad Sabaghan; Masoud Foroutan; Hamidreza Majidiani; Shahrzad Soltani; Milad Badri; Ali Dalir Ghaffari; Sheyda Soltani
Journal:  J Parasitol Res       Date:  2021-07-08

5.  Toxoplasma gondii Tyrosine-Rich Oocyst Wall Protein: A Closer Look through an In Silico Prism.

Authors:  Ali Asghari; Hamidreza Majidiani; Taher Nemati; Mohammad Fatollahzadeh; Morteza Shams; Razi Naserifar; Bahareh Kordi
Journal:  Biomed Res Int       Date:  2021-10-14       Impact factor: 3.411

6.  Development of a new serotyping ELISA for Toxoplasma gondii type II, type III and Africa 1 lineages using in silico peptide discovery methods, well categorized feline and human outbreak serum samples.

Authors:  Hüseyin Can; Ayşegül Aksoy Gökmen; Mert Döşkaya; Sedef Erkunt Alak; Aysu Değirmenci Döşkaya; Muhammet Karakavuk; Ahmet Efe Köseoğlu; Tuğba Karakavuk; Ceren Gül; Mervenur Güvendi; Aytül Gül; Adnan Yüksel Gürüz; Selçuk Kaya; Aurélien Mercier; Cemal Ün
Journal:  BMC Infect Dis       Date:  2022-01-31       Impact factor: 3.090

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.